Propanc Biopharma Inc. (NASDAQ:PPCB) stock surged on Thursday after compelling preclinical and early translational data for its primary drug candidate, PRP, focused on treating pancreatic ductal adenocarcinoma.
The biopharmaceutical company reported that PRP significantly inhibited tumor progression and extended overall survival rates in advanced animal models of the disease.
Exceptional Preclinical Tumor Inhibition
In advanced orthotopic and patient-derived xenograft models, administering PRP intravenously three times weekly delivered a mean tumor growth inhibition of over 90% compared to vehicle controls.
The therapy also markedly diminished metastatic spread within the liver and peritoneum. Furthermore, the data highlighted PRP’s ability to remodel the tumor microenvironment.
